Designing opioids that deter abuse

Pain Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Raffa, Robert B ^a   Pergolizzi, Joseph V ^b,c   Muñiz, Edmundo ^d   Taylor, Robert ^e   Pergolizzi, Jason ^e  

^a TEMPLE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Kirax Corporation Inc   (United States)

^e NEMA Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873836217     PISSN: 20901542     EISSN: 20901550     Source Type: Journal    
DOI: 10.1155/2012/282981     Document Type: Review

References (71)

1. Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. Morbidity and Mortality Weekly Report 2010 59 23 705 709
2. Anon, Administration D. E., Controlled substances act, part B. Authority and criteria for classification of substances. 21 United States Code 2004 Washington, DC, USA Office of Diversion Control
3. SAMHSA,. Results from the 2009 National Survey on Drug Use and Health: Detailed tables, http://oas.samhsa.gov/NSDUH/2k9NSDUH/tabs/Sect1peTabs54to58. pdf, 2010
4. APA, Diagnostic and Statistical Manual of Mental Disorders 2000 4th Washington, DC, USA American Psychiatric Association
5. Budman S. H., Grimes Serrano J. M., Butler S. F., Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduction Journal 2009 6 8 15 2-s2.0-67650069173 10.1186/1477-7517-6-8
6. Butler S. F., Budman S. H., Licari A., Cassidy T. A., Lioy K., Dickinson J., Brownstein J. S., Benneyan J. C., Green T. C., Katz N., National addictions vigilance intervention and prevention program (NAVIPPRO ™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiology and Drug Safety 2008 17 12 1142 1154 2-s2.0-59649085663 10.1002/pds.1659
7. Katz N. P., Adams E. H., Chilcoat H., Colucci R. D., Comer S. D., Goliber P., Grudzinskas C., Jasinski D., Lande S. D., Passik S. D., Schnoll S. H., Sellers E., Travers D., Weiss R., Challenges in the development of prescription opioid abuse-deterrent formulations. Clinical Journal of Pain 2007 23 8 648 660 2-s2.0-34648813683 10.1097/AJP.0b013e318125c5e8 (Pubitemid 47462170)
8. Cicero T. J., Wong G., Tian Y., Lynskey M., Todorov A., Isenberg K., Co-morbidity and utilization of medical services by pain patients receiving opioid medications: Data from an insurance claims database. Pain 2009 144 1-2 20 27 2-s2.0-66049136043 10.1016/j.pain.2009.01.026
9. Passik S. D., Kirsh K. L., Donaghy K. B., Portenoy R. K., Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clinical Journal of Pain 2006 22 2 173 181 2-s2.0-33644929981 10.1097/01.ajp.0000161525.48245.aa (Pubitemid 44366968)
10. Portenoy R. K., Opioid therapy for chronic nonmalignant pain: a review of the critical issues. Journal of Pain and Symptom Management 1996 11 4 203 217 2-s2.0-0030002083 10.1016/0885-3924(95)00187-5 (Pubitemid 26102522)
11. Webster L. R., Webster R. M., Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Medicine 2005 6 6 432 442 2-s2.0-30944460282 10.1111/j.1526-4637.2005.00072.x (Pubitemid 43110296)
12. Comer S. D., Sullivan M. A., Vosburg S. K., Kowalczyk W. J., Houser J., Abuse liability of oxycodone as a function of pain and drug use history. Drug and Alcohol Dependence 2010 109 1-3 130 138 2-s2.0-77953082525 10.1016/j.drugalcdep.2009.12.018
13. Zacny J. P., Gutierrez S., Bolbolan S. A., Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users. Drug and Alcohol Dependence 2005 78 3 243 252 2-s2.0-18844420034 10.1016/j.drugalcdep.2004.11.009 (Pubitemid 40694046)
14. Zacny J. P., Gutierrez S., Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 2003 170 3 242 254 2-s2.0-0344513435 10.1007/s00213-003-1540- 9 (Pubitemid 37491603)
15. Cicero T. J., Ellis M. S., Surratt H. L., Effect of abuse-deterrent formulation of oxyContin. New England Journal of Medicine 2012 367 2 187 189 10.1056/NEJMc1204141
16. Katz N., Clinical Studies of Abuse Deterrent Opioid Analgesics: Definitions, Current Approaches, and Critical Issues 2009 Arlington, Va, USA IMMPACT-X
17. Cicero T. J., Ellis M. S., Paradis A., Ortbal Z., Determinants of fentanyl and other potent opioid agonist misuse in opioid-dependent individuals. Pharmacoepidemiology and Drug Safety 2010 19 10 1057 1063 2-s2.0-78751623078 10.1002/pds.1989
18. Passik S., Kirsh K., Smith H. S., Passik S., Chemical coping: the clinical middle ground. Pain and Chemical Dependency 2008 New York, NY, USA Oxford University Press
19. Booth, A Brief History of Opium 2010
20. American College of Physicians,. Aberrant Drug-Related Behaviors, http://www.acponline.org/about-acp/chapters/az/aberrant.pdf, 2012
21. American Society of Addiction Medicine,. Public Policy Statement: Definition of Addiction, http://www.asam.org/for-the-public/definition-of- addiction, 2011
22. Association A. P., Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition (Text Revision) 2000 4th Arlington, Va, USA American Psychiatric Publishing
23. American Academy of Pain Medicine, The American Pain Society, The American Society of Addition Medicine, Definitions related to the use of opioids for the treatment of pain. Wisconsin Medical Journal 2001 100 5 28 29
24. Zamloot M., Chao W., Kang L. L., Ross J., Fu R., Remoxy ®:A novel formulation of extended-release oxycodone developed using the ORADUR ® technology. International Journal of Applied Research in Veterinary Medicine 2010 10 3 88 96 2-s2.0-78649436143
25. Acura,. Acuracet, http://acurapharm.com/products/acuracet-tablets/, 2010
26. Acura,. Vycavert, http://acurapharm.com/products/vycavert-tablets/, 2010
27. Pharmaceutical,. C. Central Nervous System, Product Pipeline, http://www.collegiumpharma.com/products/cns.html, 2010
28. Intellipharmaceutics,. Rexista Oxycodone, http://www. intellipharmaceutics.com/oxycodone.cfm, 2010
29. Haddox J., Henningfield J. E., Mannion R.,. A new formulation of OxyContin (oxycodone HCl controlled-release) tablets, http://www.fda.gov/ohrms/ DOCKETS/ac/08/slides/2008-4356s1-05-Purdue.pdf, 2008
30. TheraQuest,. TheraQuest Bioscience, Inc's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA, BioSpace, http://www.biospace.com/news-story. aspx?NewsEntityId=117355, 2008
31. Anon,. US orphan status for TheraQuest's TQ-1017, The Pharma Letter, http://www.thepharmaletter.com/file/41950/us-orphan-status-for-theraquests-tq- 1017.html, 2005
32. TheraQuest,. TheraQuest Biosciences, Inc., unveils new pain management product pipeline, Press release, http://www.biospace.com/news-story.aspx? NewsEntityId=185046, 2010
33. Labopharm,. DDS-08B: Abuse/misuse-deterrent formulation of twice-daily oxycodone-acetaminophen, http://www.labopharm.com/default.aspx?id=217, 2010
34. Pharmaceuticals N.,. EXALGO (hydromorphone HCl) Extended-Release Tablets CII, Joint Meeting Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee 2009 September 23, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM183035.pdf, 2009
35. Pisgah,. Therapeutic discovery grant accelerates investigational new drug with abuse deterrent technology, Press release, http://www.pisgahlabs.com/ General/PressRelease.aspx, 2010
36. Egalet,. Technology overview, http://www.egalet.com/index.dsp?area=7, 2009
37. Ridgway D., Sopata M., Burneckis A., Jespersen L., Andersen C., Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. Journal of Pain and Symptom Management 2010 39 4 712 720 2-s2.0-77951015384 10.1016/j.jpainsymman.2009.08. 013
38. Anon, Embeda Package Insert 2009 Bristol, Tenn, USA King Pharmacenticals, Inc
39. Anon,. Phase 2 results of investigational abuse-deterrent opioid ALO-01 presented by Alpharma, Medical News Today, http://www.medicalnewstoday.com/ printerfriendlynews.php?newsid=85689, 2007
40. Webster L., Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Medicine 2009 10 2 S124 S133 2-s2.0-68449100511 10.1111/j.1526-4637.2009.00672.x
41. Anon,. Talwin Nx Civ Package Insert, http://products.sanofi-aventis.us/ talwin-nx/talwin-nx.pdf, 2008
42. Anon,. Treatment with Suboxone Film: understanding the benefits, http://www.suboxone.com/patients/about-suboxone/Default.aspx, 2010
43. Acura,. Acurox Tablets, http://acurapharm.com/products/acurox-without- niacin-tablets/, 2010
44. Anon, Guidance for Industry: Assessment of Abuse Potential of Drugs 2010 Silver Spring, Md, USA U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research
45. Gershell L., Goater J. J., Making gains in pain. Nature Reviews Drug Discovery 2006 5 11 889 890 2-s2.0-33750509177 10.1038/nrd2179 (Pubitemid 44660601)
46. Akbik H., Butler S. F., Budman S. H., Fernandez K., Katz N. P., Jamison R. N., Validation and clinical application of the screener and opioid assessment for patients with pain (SOAPP). Journal of Pain and Symptom Management 2006 32 3 287 293 2-s2.0-33748603457 10.1016/j.jpainsymman.2006.03.010 (Pubitemid 44376443)
47. Butler S. F., Fernandez K., Benoit C., Budman S. H., Jamison R. N., Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). Journal of Pain 2008 9 4 360 372 2-s2.0-40949118164 10.1016/j.jpain.2007.11.014
48. Butler S. F., Budman S. H., Fernandez K., Jamison R. N., Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004 112 1-2 65 75 2-s2.0-5644303369 10.1016/j.pain.2004.07.026 (Pubitemid 39371021)
49. Butler S. F., Benoit C., Budman S. H., Fernandez K. C., McCormick C., Venuti S. W., Katz N., Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduction Journal 2006 3 2-s2.0-33644505488 10.1186/1477-7517-3-5
50. Berrendero F., Kieffer B. L., Maldonado R., Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in -opioid receptor knock-out mice. Journal of Neuroscience 2002 22 24 10935 10940 2-s2.0-0037114980 (Pubitemid 36005169)
51. Sellers E. M., Schuller R., Romach M. K., Horbay G. L., Relative abuse potential of opioid formulations in Canada: a structured field study. Journal of Opioid Management 2006 2 4 219 227 2-s2.0-33947222652
52. Kieffer B. L., Opioids: first lessons from knockout mice. Trends in Pharmacological Sciences 1999 20 1 19 26 2-s2.0-0033013383 10.1016/S0165- 6147(98)01279-6 (Pubitemid 29304521)
53. Rosenberg M., Drug abuse in oral and maxillofacial training programs. Journal of Oral and Maxillofacial Surgery 1986 44 6 458 462 2-s2.0-0022498024 (Pubitemid 16046533)
54. Ward C. F., Ward G. C., Saidman L. J., Drug abuse in anesthesia training programs. A survey: 1970 through 1980. Journal of the American Medical Association 1983 250 7 922 925 2-s2.0-0020562699 10.1001/jama.250.7.922 (Pubitemid 13033145)
55. Silsby H. D., Kruzich D. J., Hawkins M. R., Fentanyl citrate abuse among health care professionals. Military Medicine 1984 149 4 227 228 2-s2.0-0021670628 (Pubitemid 15144604)
56. Volkow N. D., McLellan T. A., Cotto J. H., Karithanom M., Weiss S. R. B., Characteristics of opioid prescriptions in 2009. Journal of the American Medical Association 2011 305 13 1299 1301 2-s2.0-79953735288 10.1001/jama.2011.401
57. Butler S. F., Fernandez K. C., Chang A., Benoit C., Morey L. C., Black R., Katz N., Measuring attractiveness for abuse of prescription opioids. Pain Medicine 2010 11 1 67 80 2-s2.0-74049140024 10.1111/j.1526-4637.2009.00736.x
58. Wilsey B. L., Fishman S., Li C. S., Storment J., Albanese A., Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial. Pharmacology Biochemistry and Behavior 2009 94 1 98 107 2-s2.0-70349194368 10.1016/j.pbb.2009.07.014
59. O'Connor E. C., Mead A. N., Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans. Pharmacology Biochemistry and Behavior 2010 96 3 279 286 2-s2.0-77954762744 10.1016/j.pbb.2010.05.018
60. Katz J. L., Goldberg S. R., Preclinical assessment of abuse liability of drugs. Agents and Actions 1988 23 1-2 18 26 2-s2.0-0023878295 (Pubitemid 18061039)
61. Abreu M. E., Bigelow G. E., Fleisher L., Walsh S. L., Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 2001 154 1 76 84 2-s2.0-0035117999 10.1007/s002130000624 (Pubitemid 32186518)
62. Stoops W. W., Hatton K. W., Lofwall M. R., Nuzzo P. A., Walsh S. L., Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology 2010 212 2 193 203 2-s2.0-77957374297 10.1007/s00213-010-1942-4
63. Evans S. M., Cone E. J., Henningfield J. E., Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. Journal of Pharmacology and Experimental Therapeutics 1996 279 3 1345 1356 2-s2.0-0030431324 (Pubitemid 27166783)
64. Hill H. F., Coda B. A., Tanaka A., Schaffer R., Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesthesia and Analgesia 1991 72 3 330 336 2-s2.0-0025896735
65. Stauffer J., Setnik B., Sokolowska M., Romach M., Johnson F., Sellers E., Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clinical Drug Investigation 2009 29 12 777 790 2-s2.0-70449426117 10.2165/11530800-000000000-00000
66. Schneider J. P., Matthews M., Jamison R. N., Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010 24 10 805 810 2-s2.0-77956707359 10.2165/11584260-000000000-00000
67. Stoller K. B., Bigelow G. E., Walsh S. L., Strain E. C., Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001 154 3 230 242 2-s2.0-0035084767 10.1007/s002130000637 (Pubitemid 32247184)
68. Strain E. C., Stoller K., Walsh S. L., Bigelow G. E., Effects of buprenorphine versus buprenorphine/naloxone tablets in non- dependent opioid abusers. Psychopharmacology 2000 148 4 374 383 2-s2.0-0034033451 (Pubitemid 30169755)
69. Mammen K., Bell J., The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opinion on Pharmacotherapy 2009 10 15 2537 2544 2-s2.0-70349406398 10.1517/14656560903213405
70. Walsh S. L., Nuzzo P. A., Lofwall M. R., Holtman J. R., The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug and Alcohol Dependence 2008 98 3 191 202 2-s2.0-53049102893 10.1016/j.drugalcdep.2008.05.007
71. Ruan X., Chen T., Gudin J., Couch J. P., Chiravuri S., Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. Journal of Opioid Management 2010 6 4 300 303 2-s2.0-77957313928 10.5055/jom.2010.0028